John Quisel Sells 33,000 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John Quisel sold 33,000 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $74.96, for a total transaction of $2,473,680.00. Following the completion of the transaction, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at approximately $16,945,757.44. This represents a 12.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Disc Medicine Stock Up 1.3%

IRON stock opened at $76.02 on Thursday. The stock has a market capitalization of $2.90 billion, a P/E ratio of -11.48 and a beta of 0.97. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.00 and a current ratio of 24.00. Disc Medicine, Inc. has a one year low of $40.00 and a one year high of $99.50. The company has a 50 day moving average price of $70.92 and a two-hundred day moving average price of $69.93.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03). As a group, sell-side analysts expect that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in Disc Medicine by 110.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after buying an additional 828,248 shares during the period. BVF Inc. IL purchased a new stake in Disc Medicine during the fourth quarter worth approximately $51,616,000. Jennison Associates LLC purchased a new stake in Disc Medicine during the fourth quarter worth approximately $42,252,000. Perceptive Advisors LLC acquired a new stake in shares of Disc Medicine in the fourth quarter worth $35,794,000. Finally, RA Capital Management L.P. increased its position in shares of Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after acquiring an additional 399,026 shares in the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on IRON shares. Morgan Stanley raised their price target on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Wedbush reissued an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. Finally, Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $104.44.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.